Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)
Could Rifaximin Modify the Pathogenesis of NAFLD? AMulticenter, Randomized, Double-Blind, Placebo-Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Mansoura, Egypt
- Nasser H Mousa,MD,mousa_medic@yahoo.com. +201227029213
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- women or men aged 18-65 years.
- biopsy-proven NASH without or with mild to moderate fibrosis (fibrosis stage 0-3)in the preceding year.
- persistently abnormal ALT on 2 occasions.
- participants have provided written informed consent before screening.
- all patients counseled about the standard of care treatment (e.g., diet andexercise).
- Strict requirements for weight stability between the time of biopsy and study entry.
Exclusion Criteria:
- Cirrhotic NAFLD (METAVIR stage 4).
- Combined viral hepatitis B and C infection.
- increased alcohol intake (>20 g/day) and hypothyroidism.
- co-existence of another type of biliary tract or pancreatic or liver diseases
- lactating or pregnant women.
- allergy to rifamycin or rifaximin.
- systemic inflammatory conditions (e.g. Connective tissue diseases and inflammatory bowel diseases).
- bariatric surgery and blind loop.
- evidence of hepatic decompensation (ascites, hepatic encephalopathy, and varices),
- history of myocardial infarction and/ or stroke within 6 months.
- drugs that alter the gut flora e.g. Lactulose, systemic antibiotic, cholestyramine within three months, (l) cancers especially HCC, and (m)patients with renal impairment (estimated GFR <60ml/min/1.73m2).
(n) Major dose change orintiation of biguanides, metformin, thiazolidinediones, insulin, fibrates, statins, and anti-obesity medications within three months before the onset of the study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
1
Rifaxmin group
|
Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
|
|
2
placebo group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
serum ALT
Time Frame: 6 months
|
U/l
|
6 months
|
|
serum endotoxins
Time Frame: 6 months
|
EU/ml
|
6 months
|
|
TLR-4
Time Frame: 6 months
|
ng/ml
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fasting Glucose
Time Frame: 6 months
|
mg/dl
|
6 months
|
|
, Insulin,
Time Frame: 6 months
|
μIU/ml
|
6 months
|
|
CK-18,TNF-α, IL-6, IL 10
Time Frame: 6 months
|
pg/ml
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- R/16.02.80
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.